1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc.

CGTX
Cognition Therapeutics, Inc.US flagNASDAQ Global Market
1.03
USD
-0.02
- -
92.18MMarket Cap

Total Valuation

Cognition Therapeutics, Inc. carries a market capitalization of 92.18M, placing it among publicly traded companies globally. Its enterprise value stands at 75.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap92.18M
Enterprise Value75.89M

Share Statistics

Cognition Therapeutics, Inc. currently has 95.06M shares outstanding.

Shares Outstanding95.06M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio3.31
P/TBV Ratio3.31
P/FCF Ratio-5.59
P/OCF Ratio-5.59

Financial Position

Cognition Therapeutics, Inc. maintains a current ratio of 7.03, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.78, indicating elevated leverage, while an interest coverage ratio of -1,357.31 demonstrates limited ability to service its debt obligations.

Current Ratio7.03
Quick Ratio6.78
Debt / Equity1.78
Debt / EBITDA-0.03
Interest Coverage-1,357.31

Financial Efficiency

Return on Equity (ROE)-83.76
Return on Assets (ROA)-57.33
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Cognition Therapeutics, Inc.'s stock has declined approximately -60.23166% over the past 52 weeks. The 50-day moving average sits at 1.02, while the 200-day moving average is 1.19.

Beta (5Y)N/A
52-Week Price Change-60.23166%
50-Day Moving Average1.02
200-Day Moving Average1.19
Average Volume (20 Days)N/A

Income Statement

EBITDA reached -17.64M, while operating income came in at -17.89M.

RevenueN/A
Gross ProfitN/A
Operating Income-17.89M
Pretax Income-16.77M
Net Income-16.77M
EBITDA-17.64M
EBIT-17.89M
Earnings Per Share (EPS)-0.20

Balance Sheet

Cognition Therapeutics, Inc. holds 34.01M in cash and equivalents against 589,000.00 in total debt, resulting in a net debt position of -33.93M. Total book value stands at 33.02M, with working capital of 32.85M providing operational flexibility.

Cash & Cash Equivalents34.01M
Total Debt589,000.00
Net Debt-33.93M
Equity (Book Value)33.02M
Book Value Per Share0.35
Working Capital32.85M

Cash Flow

Cognition Therapeutics, Inc. produced -17.68M in operating cash flow over the past twelve months. After subtracting -20,000.00 in capital expenditures, free cash flow totaled -17.70M - equivalent to -0.21 per share.

Operating Cash Flow-17.68M
Capital Expenditures-20,000.00
Free Cash Flow-17.70M
FCF Per Share-0.21

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-37.41
FCF Yield-17.88

Scores

Cognition Therapeutics, Inc. posts an Altman Z-Score of 3.21, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.21